226 related articles for article (PubMed ID: 22515611)
21. Pharmacogenetics of endocrine therapy for breast cancer.
Higgins MJ; Stearns V
Annu Rev Med; 2011; 62():281-93. PubMed ID: 21226615
[TBL] [Abstract][Full Text] [Related]
22. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.
Kiyotani K; Mushiroda T; Zembutsu H; Nakamura Y
J Hum Genet; 2013 Jun; 58(6):327-33. PubMed ID: 23657426
[TBL] [Abstract][Full Text] [Related]
23. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.
Newman WG; Hadfield KD; Latif A; Roberts SA; Shenton A; McHague C; Lalloo F; Howell S; Evans DG
Clin Cancer Res; 2008 Sep; 14(18):5913-8. PubMed ID: 18794105
[TBL] [Abstract][Full Text] [Related]
24. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.
Briest S; Stearns V
Clin Adv Hematol Oncol; 2009 Mar; 7(3):185-92. PubMed ID: 19398943
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Gaston C; Kolesar J
Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
[TBL] [Abstract][Full Text] [Related]
26. Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
Dieudonné AS; Lambrechts D; Claes B; Vandorpe T; Wildiers H; Timmerman D; Billen J; Leunen K; Amant F; Berteloot P; Smeets A; Paridaens R; Weltens C; Van Limbergen E; Van den Bogaert W; Vergote I; Van Huffel S; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 Dec; 118(3):531-8. PubMed ID: 19597703
[TBL] [Abstract][Full Text] [Related]
27. The ethics of CYP2D6 testing for patients considering tamoxifen.
Hartman AR; Helft P
Breast Cancer Res; 2007; 9(2):103. PubMed ID: 17433116
[TBL] [Abstract][Full Text] [Related]
28. CYP2D6 and tamoxifen: DNA matters in breast cancer.
Hoskins JM; Carey LA; McLeod HL
Nat Rev Cancer; 2009 Aug; 9(8):576-86. PubMed ID: 19629072
[TBL] [Abstract][Full Text] [Related]
29. Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
Stingl JC; Parmar S; Huber-Wechselberger A; Kainz A; Renner W; Seeringer A; Brockmöller J; Langsenlehner U; Krippl P; Haschke-Becher E
Curr Med Res Opin; 2010 Nov; 26(11):2535-42. PubMed ID: 20849243
[TBL] [Abstract][Full Text] [Related]
30. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
Goetz MP; Kamal A; Ames MM
Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
[TBL] [Abstract][Full Text] [Related]
31. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
[TBL] [Abstract][Full Text] [Related]
32. Significant Effect of Polymorphisms in
Zembutsu H; Nakamura S; Akashi-Tanaka S; Kuwayama T; Watanabe C; Takamaru T; Takei H; Ishikawa T; Miyahara K; Matsumoto H; Hasegawa Y; Kutomi G; Shima H; Satomi F; Okazaki M; Zaha H; Onomura M; Matsukata A; Sagara Y; Baba S; Yamada A; Shimada K; Shimizu D; Tsugawa K; Shimo A; Tan EY; Hartman M; Chan CW; Lee SC; Nakamura Y
Clin Cancer Res; 2017 Apr; 23(8):2019-2026. PubMed ID: 27797974
[No Abstract] [Full Text] [Related]
33. CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart.
Skaar TC; Desta Z
Clin Pharmacol Ther; 2018 May; 103(5):755-757. PubMed ID: 29473149
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy.
de Vries Schultink AHM; Huitema ADR; Beijnen JH
Breast; 2018 Dec; 42():38-40. PubMed ID: 30153552
[TBL] [Abstract][Full Text] [Related]
35. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
[TBL] [Abstract][Full Text] [Related]
36. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells.
Wu X; Hawse JR; Subramaniam M; Goetz MP; Ingle JN; Spelsberg TC
Cancer Res; 2009 Mar; 69(5):1722-7. PubMed ID: 19244106
[TBL] [Abstract][Full Text] [Related]
37. Impact of CYP2D6 polymorphisms on endoxifen concentrations and breast cancer outcomes.
Hwang GS; Bhat R; Crutchley RD; Trivedi MV
Pharmacogenomics J; 2018 Apr; 18(2):201-208. PubMed ID: 28762370
[TBL] [Abstract][Full Text] [Related]
38. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
[TBL] [Abstract][Full Text] [Related]
39. Tamoxifen benefits and CYP2D6 testing in women with hormone receptor-positive breast cancer.
Kaplan M; Mahon SM
Clin J Oncol Nurs; 2013 Apr; 17(2):174-9. PubMed ID: 23538253
[TBL] [Abstract][Full Text] [Related]
40. CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.
Hertz DL; Kidwell KM; Hilsenbeck SG; Oesterreich S; Osborne CK; Philips S; Chenault C; Hartmaier RJ; Skaar TC; Sikora MJ; Rae JM
Breast Cancer Res Treat; 2017 Nov; 166(1):277-287. PubMed ID: 28730340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]